Somewhat Positive Press Coverage Somewhat Unlikely to Affect Sucampo Pharmaceuticals (SCMP) Stock Price

News articles about Sucampo Pharmaceuticals (NASDAQ:SCMP) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sucampo Pharmaceuticals earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.0695927836457 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

• Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Quarterly Sales of $56.86 Million (americanbankingnews.com)
• Tale of the Ticker: Education Realty Trust Inc (EDR), Sucampo Pharmaceuticals Inc (SCMP) Moving on Volume – FLBC News (flbcnews.com)
• Health Care Sector Update for 08/21/2017: SCMP,CHRS,CRME – Nasdaq (nasdaq.com)
• Sucampo Pharmaceuticals, Inc. (SCMP) Internals Are Exhibiting Optimistic Signs – StockNewsGazette (stocknewsgazette.com)
• Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : August 22, 2017 (finance.yahoo.com)

Shares of Sucampo Pharmaceuticals (SCMP) traded up 0.89% during trading on Friday, hitting $11.30. The stock had a trading volume of 64,033 shares. Sucampo Pharmaceuticals has a 1-year low of $9.30 and a 1-year high of $17.55. The company’s market capitalization is $523.47 million. The firm has a 50-day moving average of $10.72 and a 200 day moving average of $10.66.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The company had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. During the same period last year, the company posted $0.24 EPS. Sucampo Pharmaceuticals’s revenue was up 15.3% on a year-over-year basis. Equities research analysts predict that Sucampo Pharmaceuticals will post $1.02 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on SCMP. Zacks Investment Research raised Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Maxim Group reaffirmed a “buy” rating and set a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. BidaskClub downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Roth Capital set a $30.00 price objective on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Sucampo Pharmaceuticals has a consensus rating of “Buy” and an average target price of $17.33.

COPYRIGHT VIOLATION WARNING: “[[title]]” was posted by [[site]] and is owned by of [[site]]. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at [[permalink]].

In other Sucampo Pharmaceuticals news, insider Jones W. Bryan purchased 4,700 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was bought at an average cost of $10.60 per share, with a total value of $49,820.00. Following the transaction, the insider now directly owns 4,700 shares in the company, valued at approximately $49,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.13% of the company’s stock.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.